{
    "nct_id": "NCT03449199",
    "official_title": "A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess Safety, Tolerability, and Renal Effects of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria",
    "inclusion_criteria": "* Type 2 diabetes treated with ≥1 glucose-lowering medication for at least 12 months\n* UACR 200 to 3000 mg/g\n* eGFR ≥30 ml/min/1.73m2\n* Treated with at least the minimal recommended dose of an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB), but not both\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of Type 1 diabetes\n* Women who are breast feeding\n* Treatment with any uric acid-lowering therapy within previous 2 weeks\n* History of intolerance to any XO (xanthine oxidase) inhibitor\n* History of a gout flare requiring pharmacologic treatment\n* History or presence of tophaceous gout\n* History of immunosuppressant treatment for any known or suspected renal disorder\n* History of a non-diabetic form of renal disease\n* Glycosylated hemoglobin (HbA1c) >11%\n* sUA <4.0 mg/dL or >10.0 mg/dL\n* Positive urinary pregnancy test\n* Dialysis for acute renal failure within previous 6 months\n* Renal allograft in place or a scheduled kidney transplant within the next 22 weeks\n* Congenital or acquired solitary kidney",
    "miscellaneous_criteria": ""
}